Attempts to enhance the eradication rate of Helicobacter pylori infection

World Journal of Gastroenterology

Volumn 20, Issue 18, 2014, Pages 5252-5262

  Bang, Chang Seok ^a   Baik, Gwang Ho ^a  

^a Hallym University College of Medicine   (South Korea)

Author keywords

Antimicrobial drug resistance; Clarithromycin; Helicobacter pylori; Metronidazole; Microbial sensitivity tests

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH; BISMUTH CITRATE; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; DOXYCYCLINE; FURAZOLIDONE; GARENOXACIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITAZOXANIDE; OMEPRAZOLE; PROBIOTIC AGENT; PRONASE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RIFABUTIN; RUFLOXACIN; SIMVASTATIN; SITAFLOXACIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG; VACCINE; VITAMIN; ANTIINFECTIVE AGENT; CYP2C19 PROTEIN, HUMAN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; EUCALYPTUS; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HUMAN; IMMUNOTHERAPY; LACTOBACILLUS GASSERI; MEDICATION COMPLIANCE; MEDICINE; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHYTOMEDICINE; PLANT LEAF; PLANT ROOT; POISON IVY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SACCHAROMYCES BOULARDII; TERMINALIA; ANIMAL; BIOTRANSFORMATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2C19; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INDIVIDUALIZED MEDICINE; MICROBIAL SENSITIVITY TESTS; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84900394270     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i18.5252     Document Type: Article

References (113)

1. Hong SN, Lee SM, Kim JH, Lee TY, Kim JH, Choe WH, Lee SY, Cheon YK, Sung IK, Park HS, Shim CS. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci 2012; 57: 2184-2194 [PMID: 22669208 DOI: 10.1007/s10620-012-2245-x]
2. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013; 108: 208-215 [PMID: 23208272 DOI: 10.1038/ajg.2012.407]
3. Trikudanathan G, Philip A, Dasanu CA, Baker WL. Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 2011; 12: 26-31 [PMID: 21206097]
4. Banić M, Franceschi F, Babić Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2012; 17 Suppl 1: 49-55 [PMID: 22958156 DOI: 10.1111/ j.1523-5378.2012.00983.x]
5. Chen BF, Xu X, Deng Y, Ma SC, Tang LQ, Zhang SB, Chen ZF. Relationship between Helicobacter pylori infection and serum interleukin-18 in patients with carotid atherosclerosis. Helicobacter 2013; 18: 124-128 [PMID: 23121308 DOI: 10.1111/hel.12014]
6. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
7. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
8. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-278 [PMID: 17669098 DOI: 10.1111/j.1523-5378.2007.00518.x]
9. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-331 [PMID: 18446147 DOI: 10.1038/ncpgasthep1138]
10. Gisbert JP, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a metaanalysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-1328 [PMID: 11012477]
11. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19: 409-414 [PMID: 21188333]
12. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20: 299-304 [PMID: 21961099]
13. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
14. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825 [PMID: 17608775]
15. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]
16. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x]
17. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. Korean J Gastroenterol 2009; 54: 269-278 [PMID: 19934608]
18. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-1604 [PMID: 20427808 DOI: 10.1056/NEJMcp1001110]
19. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15: 233-238 [PMID: 20557366 DOI: 10.1111/j.1523-5378.2010.00758.x]
20. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357 [PMID: 17635369 DOI: 10.1111/ j.1365-2036.2007.03386.x]
21. Garcia N, Calvet X, Gené E, Campo R, Brullet E. Limited usefulness of a seven-day twice-a-day quadruple therapy. Eur J Gastroenterol Hepatol 2000; 12: 1315-1318 [PMID: 11192320]
22. Perri F, Festa V, Merla A, Quitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter 2002; 7: 99-104 [PMID: 11966868]
23. Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012; 53: 273-276 [PMID: 22511052]
24. Akyildiz M, Akay S, Musoglu A, Tuncyurek M, Aydin A. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med 2009; 20: 53-57 [PMID: 19237093 DOI: 10.1016/j.ejim.2008.04.003]
25. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, openlabel, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913 [PMID: 21345487 DOI: 10.1016/s0140-6736(11)60020-2]
26. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567 [PMID: 12650788]
27. Saleem A, Qasim A, O'Connor HJ, O'Morain CA. Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther 2009; 7: 793-799 [PMID: 19735221 DOI: 10.1586/eri.09.55]
28. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-1470 [PMID: 20947881 DOI: 10.1136/gut.2010.215350]
29. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11 [PMID: 12493781]
30. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-379; quiz 1080 [PMID: 19844205 DOI: 10.1038/ajg.2009.555]
31. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-1357 [PMID: 17566020 DOI: 10.1136/gut.2007.125658]
32. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563 [PMID: 17438314]
33. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-931 [PMID: 18490667]
34. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009; 34: 41-53 [PMID: 19125902 DOI: 10.1111/j.1365-2710.2008.00969.x]
35. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, Park KS, Lee SH, Kim KO, Jeon SW. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012; 35: 56-65 [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x]
36. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-1105 [PMID: 21923713 DOI: 10.1111/j.1365-2036.2011.04843.x]
37. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213 [PMID: 23158886 DOI: 10.1016/s0140-6736(12)61579-7]
38. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012; 17: 43-48 [PMID: 22221615 DOI: 10.1111/j.1523-5378.2011.00896.x]
39. Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, Nishimura H, Ohkuma K, Oda K. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998; 33: 640-645 [PMID: 9773927]
40. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/ metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-58 [PMID: 9546119]
41. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol 2013; 47: 228-232 [PMID: 22858517 DOI: 10.1097/ MCG.0b013e31826015b0]
42. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41. e1 [PMID: 19804842 DOI: 10.1016/ j.cgh.2009.09.030]
43. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-118 [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x]
44. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604-617 [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x]
45. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012; 17: 282-285 [PMID: 22759328 DOI: 10.1111/j.1523-5378.2012.00953.x]
46. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384 [PMID: 15306603 DOI: 10.1136/gut.2003.022111]
47. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
48. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina A, Pozzati L. 14-day, high-dose acid suppression, non-bismuth quadruple therapies (" hybrid" vs. " concomitant") for Helicobacter pylori infection: a randomized trial. Gut 2012; 61 Suppl 3: A47
49. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128. e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]
50. Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol 2011; 4: 103-114 [PMID: 21694812 DOI: 10.1177/1756283x103 84171]
51. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for secondline treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010; 122: 413-422 [PMID: 20628905 DOI: 10.1007/s00508-010-1404-3]
52. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106: 1970-1975 [PMID: 21989146 DOI: 10.1038/ajg.2011.306]
53. Antos D, Schneider-Brachert W, Bästlein E, Hänel C, Haferland C, Buchner M, Meier E, Trump F, Stolte M, Lehn N, Bayerdörffer E. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006; 11: 39-45 [PMID: 16423088 DOI: 10.1111/j.0083-8703.2006.00375.x]
54. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V, Cavina M, Hassan C, Ierardi E, Morini S, Vaira D. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45-49 [PMID: 15963079 DOI: 10.1111/j.1365-2036.2005.02522.x]
55. Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, Accornero L, Savarino E, Mansi C, Mamone M, Vigneri S, Savarino V. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004; 2: 997-1002 [PMID: 15551252]
56. Hsu PI, Wu DC, Chen A, Peng NJ, Tseng HH, Tsay FW, Lo GH, Lu CY, Yu FJ, Lai KH. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008; 38: 404-409 [PMID: 18435764 DOI: 10.1111/j.1365-2362.2008.01951.x]
57. Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, Nomura H, Satoh K, Hori S, Inoue S, Tomokane T, Kudo M, Inaba T, Take S, Ohkusa T, Yamamoto S, Mizuno S, Kamoshida T, Amagai K, Iwamoto J, Miwa J, Kodama M, Okimoto T, Kato M, Asaka M. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol 2013; 48: 1128-1135 [PMID: 23307042 DOI: 10.1007/s00535-012-0731-8]
58. Hirata Y, Ohmae T, Yanai A, Sakitani K, Hayakawa Y, Yoshida S, Sugimoto T, Mitsuno Y, Akanuma M, Yamaji Y, Ogura K, Maeda S, Koike K. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents 2012; 39: 352-355 [PMID: 22321702 DOI: 10.1016/j.ijantimica g.2011.12.002]
59. Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y, Okada S, Fukuhara S, Hibi T. Efficacy of sitafloxacinbased rescue therapy for Helicobacter pylori after failures of first-and second-line therapies. Antimicrob Agents Chemother 2012; 56: 1643-1645 [PMID: 22203601 DOI: 10.1128/ aac.05941-11]
60. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009; 53: 1720-1721 [PMID: 19188389 DOI: 10.1128/ aac.00049-09]
61. Gu LY, Lin WW, Lu H, Chen XY, Ge ZZ, Li XB. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study. Helicobacter 2011; 16: 284-288 [PMID: 21762267 DOI: 10.1111/j.1523-5378.2011.00848.x]
62. Nishizawa T, Suzuki H, Hibi T. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr 2009; 44: 119-124 [PMID: 19308265 DOI: 10.3164/ jcbn.08-220R]
63. Pilotto A, Franceschi M, Rassu M, Furlan F, Scagnelli M. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000; 95: 833-834 [PMID: 10710100 DOI: 10.1111/j.1572-0241.2000.01900.x]
64. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35: 941-947 [PMID: 22372560 DOI: 10.1111/j.1365-2036.2012.05053.x]
65. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-221 [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x]
66. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62 [PMID: 11197288 DOI: 10.1111/ j.1572-0241.2001.03452.x]
67. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7: 225-231 [PMID: 12165029]
68. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidonebased therapies for Helicobacter pylori infection: a pooleddata analysis. Saudi J Gastroenterol 2012; 18: 11-17 [PMID: 22249086 DOI: 10.4103/1319-3767.91729]
69. Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 2012; 36: 1076-1083 [PMID: 23072648 DOI: 10.1111/apt.12089]
70. Kim SY, Jung SW, Kim JH, Koo JS, Yim HJ, Park JJ, Chun HJ, Lee SW, Choi JH. Effectiveness of three times daily lansoprazole/ amoxicillin dual therapy for Helicobacter pylori infection in Korea. Br J Clin Pharmacol 2012; 73: 140-143 [PMID: 21689141 DOI: 10.1111/j.1365-2125.2011.04048.x]
71. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, Ishizaki T, Hishida A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-323 [PMID: 17669104 DOI: 10.1111/j.1523-5378.2007.00508.x]
72. Kim YK, Kim JS, Kim BW. Recent Trends of Helicobacter pylori Eradication Therapy in Korea. Korean J Helicobacter Up Gastrointest Res 2012; 12: 219-223
73. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G. High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 19: 789-795 [PMID: 15043520 DOI: 10.1111/j.1365-2036.2004.01910.x]
74. Savarino V, Zentilin P, Pivari M, Bisso G, Raffaella Mele M, Bilardi C, Borro P, Dulbecco P, Tessieri L, Mansi C, Borgonovo G, De Salvo L, Vigneri S. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 893-900 [PMID: 10886045]
75. Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 202-206 [PMID: 12752732]
76. Woo HY, Park DI, Park H, Kim MK, Kim DH, Kim IS, Kim YJ. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter 2009; 14: 22-28 [PMID: 19191892 DOI: 10.1111/ j.1523-5378.2009.00654.x]
77. Lehours P, Siffré E, Mégraud F. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol 2011; 11: 112 [PMID: 22004003 DOI: 10.1186/14 71-230x-11-112]
78. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-1475 [PMID: 16863547 DOI: 10.1111/j.1572-0241.2006.00717.x]
79. Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther 2007; 26: 693-703 [PMID: 17697203 DOI: 10.1111/j.1365-2036.2007.03408.x]
80. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64 [PMID: 9110363]
81. Sheu BS, Fock KM. CYP2C19 genotypes and Helicobacter pylori eradication. J Gastroenterol Hepatol 2008; 23: 1163 [PMID: 18699976 DOI: 10.1111/j.1440-1746.2008.05519.x]
82. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol 2013; 62: 3-26 [PMID: 23954956]
83. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 97-107 [PMID: 19751434 DOI: 10.1111/j.1523-5378.2009.00716. x]
84. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]
85. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309-316 [PMID: 17669103 DOI: 10.1111/j.1523-5378.2007.00516. x]
86. Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15: 206-213 [PMID: 20557362 DOI: 10.1111/j.1523-5378.2010.00751.x]
87. Deguchi R, Nakaminami H, Rimbara E, Noguchi N, Sasatsu M, Suzuki T, Matsushima M, Koike J, Igarashi M, Ozawa H, Fukuda R, Takagi A. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol 2012; 27: 888-892 [PMID: 22098133 DOI: 10.1111/j.1440-1746.2011.06985.x]
88. Bekar O, Yilmaz Y, Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food 2011; 14: 344-347 [PMID: 21186984 DOI: 10.1089/jmf.2010.0099]
89. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137: 812S-818S [PMID: 17311980]
90. Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, Mograbi J. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther 2012; 36: 231-238 [PMID: 22646167 DOI: 10.1111/j.1365-2036.2012.05161.x]
91. Tokoro C, Inamori M, Koide T, Sekino Y, Iida H, Sakamoto Y, Endo H, Hosono K, Takahashi H, Yoneda M, Yasuzaki H, Ogawa M, Abe Y, Kubota K, Saito S, Kawana I, Nakajima A, Maeda S, Matsuda R, Takahashi D. Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication. Med Sci Monit 2011; 17: CR235-CR240 [PMID: 21525804]
92. Gokturk HS, Demir M, Unler GK, Erbayrak M, Sakalli M, Yilmaz U. Does long-term aspirin use have any effect on Helicobacter pylori eradication? Am J Med Sci 2011; 342: 15-19 [PMID: 21642817 DOI: 10.1097/MAJ.0b013e3182174cf1]
93. Sezikli M, Cetinkaya ZA, Güzelbulut F, Sezikli H, Özkara S, Coşgun S, Gönen C, Övünç AO. Efficacy of vitamins supplementation to therapy on Helicobacter pylori eradication in patients with low antioxidant capacity. Clin Res Hepatol Gastroenterol 2011; 35: 745-749 [PMID: 21856267 DOI: 10.1016/j.clinre.2011.07.001]
94. Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr 2011; 106: 1632-1637 [PMID: 21810287 DOI: 10.1017/s0007114511003813]
95. Hashimoto Y, Tsuiki S, Nisizawa K, Pigman W. Action of proteolytic enzymes on purified bovine submaxillary mucin. Ann N Y Acad Sci 1963; 106: 233-246 [PMID: 13960868]
96. Taniguchi Y, Yoshida Y, Kimura K, Mato M. Cytoprotection by 16,16-dimethylprostaglandin E2. Role of gastric juice and mucus gel layer. J Clin Gastroenterol 1992; 14 Suppl 1: S52-S58 [PMID: 1629578]
97. Gotoh A, Akamatsu T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, Ishida K, Ikeno T, Sugiyama A, Kawakami Y, Ota H, Katsuyama T. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 2002; 7: 183-191 [PMID: 12047324]
98. Kimura K, Ido K, Saifuku K, Taniguchi Y, Kihira K, Satoh K, Takimoto T, Yoshida Y. A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 60-63 [PMID: 7801950]
99. Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, Gomes ET. Anti-Helicobacter pylori activity of Terminalia macroptera root. Fitoterapia 2012; 83: 872-876 [PMID: 22465506 DOI: 10.1016/j.fitote.2012.03.019]
100. Njume C, Afolayan AJ, Samie A, Ndip RN. Inhibitory and bactericidal potential of crude acetone extracts of Combretum molle (Combretaceae) on drug-resistant strains of Helicobacter pylori. J Health Popul Nutr 2011; 29: 438-445 [PMID: 22106749]
101. Njume C, Afolayan AJ, Green E, Ndip RN. Volatile compounds in the stem bark of Sclerocarya birrea (Anacardiaceae) possess antimicrobial activity against drug-resistant strains of Helicobacter pylori. Int J Antimicrob Agents 2011; 38: 319-324 [PMID: 21752604 DOI: 10.1016/j.ijantimicag.201 1.05.002]
102. Ko SH, Yoo DY, Kim YJ, Choi SM, Kang KK, Kim H, Kim N, Kim JS, Kim JM. A mechanism for the action of the compound DA-6034 on NF-κB pathway activation in Helicobacter pylori-infected gastric epithelial cells. Scand J Immunol 2011; 74: 253-263 [PMID: 21623862 DOI: 10.1111/ j.1365-3083.2011.02577.x]
103. Suk KT, Kim HS, Kim MY, Kim JW, Uh Y, Jang IH, Kim SK, Choi EH, Kim MJ, Joo JS, Baik SK. In vitro antibacterial and morphological effects of the urushiol component of the sap of the Korean lacquer tree (Rhus vernicifera Stokes) on Helicobacter pylori. J Korean Med Sci 2010; 25: 399-404 [PMID: 20191039 DOI: 10.3346/jkms.2010.25.3.399]
104. Suk KT, Baik SK, Kim HS, Park SM, Paeng KJ, Uh Y, Jang IH, Cho MY, Choi EH, Kim MJ, Ham YL. Antibacterial effects of the urushiol component in the sap of the lacquer tree (Rhus verniciflua Stokes) on Helicobacter pylori. Helicobacter 2011; 16: 434-443 [PMID: 22059394 DOI: 10.1111/ j.1523-5378.2011.00864.x]
105. Xie JH, Chen YL, Wu QH, Wu J, Su JY, Cao HY, Li YC, Li YS, Liao JB, Lai XP, Huang P, Su ZR. Gastroprotective and anti-Helicobacter pylori potential of herbal formula HZJW: safety and efficacy assessment. BMC Complement Altern Med 2013; 13: 119 [PMID: 23721522 DOI: 10.1186/1472-6882-13-1 19]
106. den Hoed CM, de Vries AC, Mensink PB, Dierikx CM, Suzuki H, Capelle L, van Dekken H, Ouwendijk R, Kuipers EJ. Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial. Can J Gastroenterol 2011; 25: 207-213 [PMID: 21523262]
107. Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2011; 8: 133-140 [PMID: 21304478 DOI: 10.1038/nrgastro.2011.1]
108. Sutton P, Chionh YT. Why can't we make an effective vaccine against Helicobacter pylori? Expert Rev Vaccines 2013; 12: 433-441 [PMID: 23560923 DOI: 10.1586/erv.13.20]
109. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-496 [PMID: 1732120]
110. Sanches B, Coelho L, Moretzsohn L, Vieira G. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter 2008; 13: 572-576 [PMID: 19166424 DOI: 10.1111/ j.1523-5378.2008.00649.x]
111. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312-2316 [PMID: 10547171]
112. Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, Fischbach L, Gold B, Hyunh H, Jacobson K, Jones NL, Koletzko S, Lebel S, Moayyedi P, Ridell R, Sherman P, van Zanten S, Beck I, Best L, Boland M, Bursey F, Chaun H, Cooper G, Craig B, Creuzenet C, Critch J, Govender K, Hassall E, Kaplan A, Keelan M, Noad G, Robertson M, Smith L, Stein M, Taylor D, Walters T, Persaud R, Whitaker S, Woodland R. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol 2005; 19: 399-408 [PMID: 16010300]
113. Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y, Guarner J, Kalach N, Madrazo A, Megraud F, Oderda G. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53: 230-243 [PMID: 21558964 DOI: 10.1097/MPG.0b013e3182227e90]